# An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

> **NCT05038878** · PHASE4 · TERMINATED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 4 (actual)

## Conditions studied

- Mild Autonomous Cortisol Excess

## Interventions

- **DRUG:** Elagolix

## Key facts

- **NCT ID:** NCT05038878
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-06
- **Primary completion:** 2022-06-24
- **Final completion:** 2022-06-24
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Difficulty recruiting patients
- **Last updated:** 2025-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05038878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05038878, "An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05038878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*